This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Research Validates New Biomarkers For Risk Assessment Of Acute Kidney Injury

WASHINGTON, Feb. 6, 2013 /PRNewswire-USNewswire/ -- Two biomarkers used in combination can improve risk assessment of acute kidney injury (AKI), according to new research from an international multi-center study. AKI strikes up to seven percent of hospitalized patients and is associated with significant morbidity and mortality.

The results, published today in Critical Care, address one of the most costly and deadly conditions affecting critically ill hospitalized patients. The findings provide much needed insight into the most compelling biomarkers of acute kidney injury.

"If unchecked, AKI can lead to loss of kidney function in a patient, often resulting in lower quality of life or even death," said Dr. John Kellum, a critical care physician at UPMC. "The data show that two urinary biomarkers of AKI can tell a doctor if a patient is at risk of kidney injury."

The two-part study collected data on critically ill patients in North American and Europe.

In the first part of the study, led by Dr. Kianoush Kashani of Mayo Clinic, researchers performed an exhaustive evaluation of nearly 340 biomarkers to define the two best biomarkers with the highest correlation to risk of acute kidney injury. 

In the second part of the study, led by Dr. John Kellum, a critical care physician at UPMC and Lakhmir Chawla, anesthesiologist at The GW Medical Faculty Associates and associate professor of Anesthesiology & Critical Care medicine and of Medicine at The George Washington University School of Medicine & Health Sciences, researchers from 35 medical centers validated the effectiveness of the two novel biomarkers in 740 critically ill patients and compared their performance with other biomarkers, including serum creatinine.

  • The two novel biomarkers validated were Insulin-like growth factor-binding protein 7 (IGFBP7) and tissue inhibitor of metalloproteinases-2 (TIMP-2), both inducers of G1 cell cycle arrest, a key mechanism implicated in AKI.
  • Together IGFBP7 and TIMP-2 demonstrated an AUC of .80 (0.76 and 0.79, respectively).
  • Together IGFBP7 and TIMP-2 were superior to all commonly used markers of AKI (p<0.002), none of which achieved an AUC > 0.72.

"The results are striking not only in terms of identifying new robust markers that have improved performance characteristics when directly compared with existing methods for assessing risk of AKI, but also in terms of bolstering understanding of the mechanism of this disease," said Dr. Chawla.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,960.57 -123.23 -0.72%
S&P 500 1,978.34 -9.64 -0.48%
NASDAQ 4,449.5640 -22.5440 -0.50%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs